Annual Report 2023

CHAIRMAN’S STATEMENT 7 The United Laboratories International Holdings Limited Annual Report 2023 REVIEW OF 2023 In 2023, we achieved satisfactory operating results thanks to our active efforts to promote R&D, production and supply, and sales services. On behalf of the board of directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company” or “The United Laboratories”), I am pleased to present to our shareholders and partners the annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2023 (the “Year”). In the course of the year, the Group recorded revenue of approximately RMB13,739.9 million, representing an increase of approximately 21.2% year-on-year. Profit attributable to owners of the Company was RMB2,701.4 million, representing a year-on-year increase of 70.9%. Earnings per share were RMB148.67 cents. The Board recommends the payment of a final dividend of RMB28 cents per share and a special dividend of RMB12 cents per share for the year ended 31 December 2023. The dividend for the full year was RMB52 cents together with the distributed interim dividend of RMB12 cents per share. Made continuous breakthroughs in new drug research and development The GLP-1 drug pipeline grew vigorously with emerging new blockbuster drugs, and the coverage of multiple new indications further gave birth to enormous market potential. The Group devised a differentiated product pipeline integrating both innovative drugs and biosimilars focusing on the GLP-1 target. During the year, Class 1 innovative drug UBT251 Injection successively obtain the clinical trial approvals in China and the United States, and the Group became the first enterprise in China and the second in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1 (glucagon-like peptide-1)/ GIP (glucose-dependent insulinotropic polypeptide)/ GCG (glucagon) prepared by chemical synthetic polypeptide. Meanwhile, the Semaglutide Injection and the Liraglutide Injection also made positive progress. The Group focused on metabolism, autoimmunity, ophthalmology, anti-infection and other fields and kept expanding the ongoing new drug pipeline. During the year, the Group obtained the clinical trial approvals for TUL12101 Eye Drops, a Class 1 new drug for dry eye syndrome, and TUL01101 Tablets, a Class 1 new drug for the medium and severe atopic dermatitis. During the year, the Group earmarked the R&D spending of up to RMB808.3 million, representing an increase of 36.2% year-on-year. Innovation is the fundamental driving force for our development. Relying on the sound R&D system and mature R&D platforms, the Group will continue to promote the process of new drug R&D and listing, expand the layout of research fields with an international vision, improve the formation of high- caliber talent teams, and continuously enhance the competitiveness and creativity of the Group.